Targeted Therapeutic Agents for Colorectal Cancer

被引:23
作者
Chee, Cheng E. [1 ]
Sinicrope, Frank A. [1 ,2 ]
机构
[1] Mayo Clin, Div Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
Colorectal cancer; Targeted therapy; VEGF; EGFR; GROWTH-FACTOR RECEPTOR; POSTOPERATIVE ADJUVANT THERAPY; FLUOROURACIL PLUS LEUCOVORIN; TYROSINE KINASE INHIBITOR; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MONOCLONAL-ANTIBODY; ORAL CAPECITABINE;
D O I
10.1016/j.gtc.2010.08.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The treatment of colorectal cancer (CRC) has evolved substantially during the past decade with the advent of molecular targeted therapies Inhibitors to the vascular endothelial growth factor and epidermal growth factor receptor (EGFR) pathways have been shown to enhance the efficacy of cytotoxic chemotherapy in patients with advanced CRC and anti-EGFR antibodies demonstrate modest activity as monotherapeutic agents These biologic agents have improved patient outcomes and survival and have been incorporated into routine clinical practice establishing a new standard of care Molecular markers have recently been adopted into clinical practice with the finding that the KRAS oncogene is a predictive biomarker for anti-EGFR therapy whereby the therapeutic benefit of anti-EGFR treatment is restricted to tumors with wild-type KRAS The use of molecular targeted agents has fewer yet more specific toxicities compared with conventional cytotoxic drugs and enables a more personalized approach to cancer therapy In contrast to the results for advanced CRC, targeted therapies have not shown a benefit in the adjuvant setting for patients with resected colon cancer The goal of this review is to provide an update on the medical management of CRC, with a focus on the use of targeted therapy
引用
收藏
页码:601 / +
页数:14
相关论文
共 80 条
[71]   Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study [J].
Van Cutsem, E ;
Twelves, C ;
Cassidy, J ;
Allman, D ;
Bajetta, E ;
Boyer, M ;
Bugat, R ;
Findlay, M ;
Frings, S ;
Jahn, M ;
McKendrick, J ;
Osterwalder, B ;
Perez-Manga, G ;
Rosso, R ;
Rougier, P ;
Schmiegel, WH ;
Seitz, JF ;
Thompson, P ;
Vieitez, JM ;
Weitzel, C ;
Harper, P .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (21) :4097-4106
[72]  
van Cutsem E., 2008, NEW TREATMENT STRATE, P21
[73]   Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer [J].
Van Cutsem, Eric ;
Peeters, Marc ;
Siena, Salvatore ;
Humblet, Yves ;
Hendlisz, Alain ;
Neyns, Bart ;
Canon, Jean-Luc ;
Van Laethem, Jean-Luc ;
Maurel, Joan ;
Richardson, Gary ;
Wolf, Michael ;
Amado, Rafael G. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1658-1664
[74]  
WAGNER AD, 2009, COCHRANE DB SYST REV, V3
[75]   THE BENEFIT OF LEUCOVORIN-MODULATED FLUOROURACIL AS POSTOPERATIVE ADJUVANT THERAPY FOR PRIMARY COLON-CANCER - RESULTS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL C-03 [J].
WOLMARK, N ;
ROCKETTE, H ;
FISHER, B ;
WICKERHAM, DL ;
REDMOND, C ;
FISHER, ER ;
JONES, J ;
MAMOUNAS, EP ;
ORE, L ;
PETRELLI, NJ ;
SPURR, CL ;
DIMITROV, N ;
ROMOND, EH ;
SUTHERLAND, CM ;
KARDINAL, CG ;
DEFUSCO, PA ;
JOCHIMSEN, P .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1879-1887
[76]  
Wolmark N, 2009, J CLIN ONCOL, V27
[77]   Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy [J].
Yang, XD ;
Jia, XC ;
Corvalan, JRF ;
Wang, P ;
Davis, CG .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 38 (01) :17-23
[78]   Untangling the ErbB signalling network [J].
Yarden, Y ;
Sliwkowski, MX .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :127-137
[79]  
Zaniboni A, 1998, CANCER, V82, P2135, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2135::AID-CNCR7>3.0.CO
[80]  
2-U